U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07325500) titled 'Incretin Microdosing for Cardiometabolic Health in People With HIV' on Jan. 06.
Brief Summary: The objectives of this study are as follows:
Primary Objective
* To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy.
Secondary Objectives
* To evaluate the tolerability of semaglutide microdosing in adults with HIV.
* To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.
Stud...